Health inequalities modular update to NICE health technology evaluations: the manual (PMG36) Methods / process manual consultation NICE process and methods 31 January 2025 Highly specialised ...

Tirzepatide's gastrointestinal adverse effects could lead to dehydration and in turn a deterioration in renal function including acute renal failure. Older people and some other groups of people may ...

Tirzepatide should be thought about as an option for individual people in line with NICE's guideline on overweight and obesity management. The visual summary care pathway has an overview. Table 4 is ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the technology being ...

Anhydrous sodium thiosulfate, also known as Pedmarqsi and made by Norgine, is recommended in final draft guidance for preventing hearing loss caused by cisplatin chemotherapy in children from the ages ...

Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index ...

We have a library of over 200 quality standards and a single menu of indicators. They can be used to help define and measure quality in health, public health and social care. They can be used by ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

NICE inherited the 7 highly specialised technologies (HST) routing criteria from AGNSS (Advisory Group for National Specialised Services) in 2013. Following that, the NICE Highly Specialised ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Our final draft guidance recommends elacestrant (also called KORSERDU and made by Menarini Stemline) for treating oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (HER2-) ...